Accused of milking the CMS with co-pay kickbacks, J&J's Actelion settles case for $310M
As the Trump administration continues to pump out new proposals to guard the Centers of Medicare and Medicaid Services against high drug prices, its law enforcement arm has also been busy rounding up biopharma companies that it says have essentially bought their ways into reimbursement for their ever-more-expensive therapies.
Actelion has been made the latest example, having agreed to pay $360 million to resolve kickback allegations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.